Bernard Schneider, PA
Physician Assistant · Wilmington, DENPI 1962459925
Payments from drug & device makers
Across 92 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$234
- Novo Nordisk$191
- AstraZeneca$165
- Abbott$139
- Johnson & Johnson$134
- GSK$104
- plus $690 from 16 others
What the payments were for
- Food & beverage$1,658100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 13 | $234 |
| Novo Nordisk | 11 | $191 |
| AstraZeneca | 10 | $165 |
| Abbott | 7 | $139 |
| Johnson & Johnson | 8 | $134 |
| GSK | 6 | $104 |
| Exact Sciences | 6 | $102 |
| Biohaven Pharmaceuticals, Inc. | 5 | $90 |
| Pfizer | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Lundbeck LLC | 3 | $62 |
| Astellas Pharma US Inc | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Tactile Systems Technology Inc | 1 | $36 |
| Merck | 2 | $33 |
| AbbVie | 2 | $33 |
| Seqirus USA Inc | 1 | $26 |
| Viiv Healthcare Company | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$1,658 in reported general payments places this provider in the 80th percentile of 527 physician assistant providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $87,355 |
| EliquisApixaban | 62 | $66,465 |
| JardianceEmpagliflozin | 46 | $37,188 |
| XareltoRivaroxaban | 41 | $31,359 |
| JanuviaSitagliptin Phosphate | 16 | $21,894 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $21,091 |
| TrulicityDulaglutide | 20 | $19,749 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $17,832 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $14,152 |
| FarxigaDapagliflozin Propanediol | 13 | $11,458 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $11,386 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $10,320 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $6,607 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $4,867 |
| Atorvastatin Calcium | 234 | $3,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $191 | $87,35594 claims |
| PfizerEliquis | $75 | $66,46562 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta | $104 | $55,85091 claims |
| Boehringer IngelheimJardiance | $17 | $37,18846 claims |
| MerckJanuvia, Janumet | $33 | $36,04730 claims |
| Johnson & JohnsonXarelto | $134 | $31,35941 claims |
| Lilly USA, LLCTrulicity | $234 | $19,74920 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $165 | $16,32525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 527 physician assistant providers in Delaware.
Other physician assistant in Wilmington
- Jason SaulWilmington$9K
- Brooke EnderleWilmington$7K
- Linhda NguyenWilmington$5K
- Matthew StumpWilmington$5K
- Christopher HoverWilmington$5K
- Julie SimsWilmington$5K
- Joan TaddeiWilmington$4K
- Gabriel PelaezWilmington$4K
- Caitlin McCarryWilmington$4K
- Samantha DelfeldWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.